Tenaya Therapeutics, Inc. Effective Income Tax Rate Reconciliation, Other Adjustments, Percent
Tenaya Therapeutics, Inc. (TNYA) reported Effective Income Tax Rate Reconciliation, Other Adjustments, Percent of -1.90% for the 12-month period ending 2024-12-31, per its 10-K filed 2025-03-10.
Financial Statements › Expense Statement › Income Tax
us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments · last filed 2025-03-10
- Tenaya Therapeutics, Inc. effective income tax rate reconciliation, other adjustments, percent for fiscal 2024 was -1.90%.
- Tenaya Therapeutics, Inc. effective income tax rate reconciliation, other adjustments, percent for fiscal 2023 was -1.20%.
- Tenaya Therapeutics, Inc. effective income tax rate reconciliation, other adjustments, percent for fiscal 2022 was -0.60%.
- Tenaya Therapeutics, Inc. effective income tax rate reconciliation, other adjustments, percent for fiscal 2021 was -1.10%.
| Period end | Effective Income Tax Rate Reconciliation, Other Adjustments, Percent 12 month |
|---|---|
| 2024-12-31 | -1.90% 10-K · filed 2025-03-10 |
| 2023-12-31 | -1.20% 10-K · filed 2025-03-10 |
| 2022-12-31 | -0.60% 10-K · filed 2024-03-18 |
| 2021-12-31 | -1.10% 10-K · filed 2023-03-08 |
| 2020-12-31 | -0.30% 10-K · filed 2022-03-23 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Caribou Biosciences, Inc. (CRBU) | United States | $0.134B | -1.79 |
| Armata Pharmaceuticals, Inc. (ARMP) | United States | $0.132B | |
| Neumora Therapeutics, Inc. (NMRA) | United States | $0.132B | -1.48 |
| enGene Therapeutics Inc. (ENGN) | $0.129B | -0.92 | |
| Humacyte, Inc. (HUMA) | United States | $0.155B | -2.26 |
| Outlook Therapeutics, Inc. (OTLK) | United States | $0.162B | -4.90 |
| Acumen Pharmaceuticals, Inc. (ABOS) | United States | $0.162B | -1.83 |
| LENZ Therapeutics, Inc. (LENZ) | United States | $0.117B | -1.41 |
| Black Diamond Therapeutics, Inc. (BDTX) | United States | $0.109B | -2.48 |
| Voyager Therapeutics, Inc. (VYGR) | United States | $0.173B | -1.99 |